Summit Therapeutics
Update in progressSMMT (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovery, development, and commercialization of therapies for patients, physicians, caregivers, and society. Its lead candidate, ivonescimab, is a bispecific antibody for immunotherapy, combining PD-1 blockade with anti-angiogenesis for NSCLC and CRC. Ivonescimab with chemotherapy is in phase III for select NSCLC and CRC settings. Markets include the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Founded 2003, based in Miami.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- -0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Robert W. Duggan
- Founded2003
- Employees265
- Websitewww.smmttx.com
Identifiers
- ISINUS86627T1088
- FIGIBBG00X3GQL76
- CUSIP86627R102
- CIK0001599298